Astellas to build drug production facility in Ireland

14 Sep 2023
www.pharmaceutical-technology.com
Astellas to build drug production facility in Ireland
Preview
Source: Pharmaceutical Technology
The new facility will allow Astellas to expand its capacity and capabilities for aseptic drug products. Credit: JHVEPhoto / Shutterstock.com.
Astellas Pharma is submitting a planning application for the construction of a new drug production facility in Tralee, County Kerry, Ireland.
To be based on the Industrial Development Authority’s greenfield site in Kerry Technology Park, the new facility will involve an investment of €330m.
Recommended Reports
Astellas to build drug production facility in Ireland
Preview
Source: Pharmaceutical Technology
ReportsSchistosomiasis mansoni Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Typ... GlobalData
Astellas to build drug production facility in Ireland
Preview
Source: Pharmaceutical Technology
ReportsEnterococcus Faecium Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type a... GlobalData
View allCompanies IntelligenceAstellas Pharma IncAstellas B.V.View all
It will allow the company to expand its capacity and capabilities for aseptic drug products.
It will also bolster stable production for supply worldwide and expedite the development and commercialisation of new antibody drugs and other products.
To be constructed on a 44.7-acre site, the three-storey building will feature a total floor area of 17,000m² and a footprint of 7,300m².
Construction is set to start in 2024, with the site operational by 2028.
The new facility will align with the company’s commitment to sustainability, integrating national and international energy and environmental design standards.
The project aims to decrease water usage by 50%, lower operational energy intensity by one-third and achieve zero waste sent to landfill.
Astellas chief manufacturing officer Hideki Shima stated: “Astellas is developing innovative drugs and technologies based on our Focus Area research and development approach, placing patients at the forefront of everything we do.
“With the new facility, Astellas will aim to strengthen our in-house production capacity and capabilities and ensure a stable supply of high-quality Astellas medicines to patients around the world.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.